SCHEMBL716249

SCHEMBL716249

COC(=O)[C@@H]1C[C@@H](Sc2ccc(F)cc2C(F)(F)F)CN1C(=O)OC(C)(C)C

nearest known ligand 0.40

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CCNT1 O60563 1/20 0.40
CDK9 P50750 1/20 0.40
NR1H2 P55055 1/20 0.39
NR1H3 Q13133 1/20 0.39
PTPN1 P18031 1/20 0.39
EPHX2 P34913 1/20 0.38
ABL1 P00519 2/20 0.37
BCR P11274 2/20 0.37
CYP1A2 P05177 1/20 0.37
POLB P06746 1/20 0.37
CYP3A4 P08684 1/20 0.37
CYP2C19 P33261 1/20 0.37
PDE4B Q07343 1/20 0.36
TACR1 P25103 3/20 0.36
AR P10275 3/20 0.36
P2RX7 Q99572 1/20 0.36
HDAC1 Q13547 1/20 0.36
HDAC2 Q92769 1/20 0.36
HSD11B1 P28845 1/20 0.34
GPBAR1 Q8TDU6 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2106441 0.88 CTSS (0.44) CCNT1CDK9NR1H2NR1H3PTPN1
SCHEMBL724889 0.88 NR1H2 (0.40) NR1H2NR1H3PTPN1EPHX2CYP1A2
SCHEMBL696198 0.81 CYP1A2 (0.50) CCNT1CDK9NR1H2NR1H3PTPN1
SCHEMBL14974487 0.80 CTSS (0.43) CCNT1CDK9NR1H2NR1H3PTPN1
SCHEMBL696817 0.80 CTSS (0.43) CCNT1CDK9NR1H2NR1H3PTPN1
SCHEMBL15184109 0.79 CYP1A2 (0.46) CCNT1CDK9NR1H2NR1H3PTPN1
SCHEMBL689919 0.79 P2RX3 (0.43) NR1H2NR1H3PTPN1ABL1BCR
SCHEMBL15169964 0.79 ALDH1A1 (0.41) NR1H2NR1H3PTPN1ABL1BCR
SCHEMBL696886 0.78 NR1H2 (0.42) NR1H2NR1H3PTPN1CYP1A2POLB
SCHEMBL14974696 0.78 NR1H2 (0.42) NR1H2NR1H3PTPN1CYP1A2POLB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2421826-B1 PROLINE DERIVATIVES AS CATHEPSIN INHIBITORS HOFFMANN LA ROCHE (CH) 2013-10-23 EP disclosed
US-8163793-B2 Proline derivatives HOFFMAN-LA ROCHE INC. (US) 2012-04-24 US disclosed
EP-2421826-A1 PROLINE DERIVATIVES AS CATHEPSIN INHIBITORS F. Hoffmann-La Roche AG (CH) 2012-02-29 EP disclosed
WO-2010121918-A1 PROLINE DERIVATIVES AS CATHEPSIN INHIBITORS F. HOFFMANN-LA ROCHE AG (CH) 2010-10-28 WO disclosed
US-20100267722-A1 NOVEL PROLINE DERIVATIVES F. HOFFMANN-LA ROCHE AG (CH) 2010-10-21 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100267722-A1 NOVEL PROLINE DERIVATIVES PRAP1, PRR12, SLC6A7 CCNT1 105/4885CDK9 2649/4885NR1H2 1251/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.